Skip to main content

Table 5 Probability of PSA for CTZ/TAZ versus MEPM

From: Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan

Strategy

Optimal (%)

CTZ/TAZ

53.3

MEPM

46.7

  1. CTZ/TAZ ceftolozane/tazobactam, MEPM Meropenem, PSA Probabilistic sensitivity analysis
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us